Martin Taylor
Direttore/Membro del Consiglio presso Charm Therapeutics Ltd.
Posizioni attive di Martin Taylor
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Impresa Management LLC (United Kingdom) | Analista di Private Equity | 01/01/2019 | - |
Charm Therapeutics Ltd.
 Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Martin Taylor
Statistiche
Distribuzione geografica
| Regno Unito | 3 |
Posizioni
| Private Equity Analyst | 1 |
| Director/Board Member | 1 |
Settori
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
| Impresa Management LLC (United Kingdom) | Finance |
Charm Therapeutics Ltd.
Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Martin Taylor
- Esperienza
